805 Shares in Insulet Co. (NASDAQ:PODD) Bought by American Trust

American Trust bought a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 805 shares of the medical instruments supplier's stock, valued at approximately $210,000.

Other large investors have also recently modified their holdings of the company. SBI Securities Co. Ltd. bought a new stake in shares of Insulet during the 4th quarter valued at approximately $36,000. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Insulet by 30.1% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier's stock worth $2,192,000 after buying an additional 1,942 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Insulet by 21.8% during the fourth quarter. Jennison Associates LLC now owns 158,342 shares of the medical instruments supplier's stock worth $41,338,000 after buying an additional 28,375 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in shares of Insulet by 4.3% in the 4th quarter. Vontobel Holding Ltd. now owns 2,423 shares of the medical instruments supplier's stock valued at $633,000 after acquiring an additional 100 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Insulet during the 4th quarter valued at $9,822,000.

Analyst Ratings Changes

A number of equities analysts have issued reports on PODD shares. Citigroup reaffirmed a "buy" rating and issued a $380.00 target price (up previously from $320.00) on shares of Insulet in a report on Thursday, May 22nd. Piper Sandler upped their price objective on Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Wolfe Research upgraded shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price on the stock in a research report on Tuesday, May 13th. Wells Fargo & Company set a $322.00 target price on shares of Insulet in a report on Monday, April 28th. Finally, Barclays upped their price target on shares of Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. Four research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $309.88.

Insulet Trading Down 0.9%

Shares of PODD stock traded down $3.09 during trading hours on Wednesday, hitting $323.55. 919,836 shares of the company were exchanged, compared to its average volume of 710,674. The company has a 50 day simple moving average of $274.57 and a two-hundred day simple moving average of $271.02. The firm has a market cap of $22.77 billion, a P/E ratio of 55.88, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a fifty-two week low of $171.61 and a fifty-two week high of $333.24.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. During the same period last year, the company posted $0.73 earnings per share. The business's quarterly revenue was up 28.8% on a year-over-year basis. Equities analysts anticipate that Insulet Co. will post 3.92 EPS for the current year.

Insider Activity at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.